Displaying 721 - 740 of 1585
Statement of Chairwoman Ramirez, Commissioner Brill, and Commissioner McSweeny - In the Matter of Health Discovery Corporation, and FTC v. Avrom Boris Lasarow, et al.
Schering-Plough Corporation, , In the Matter of
The Commission challenged Schering-Plough’s proposed $41.4 billion acquisition of Merck & Co., and required divestitures to preserve competition in markets for human and animal pharmaceuticals. The proposed consent order requires that Merck sell its interest in Merial Limited, an animal health joint venture with Sanofi-Aventis S.A., and that Schering-Plough sell its assets related to significant drugs for nausea and vomiting in humans.
Statement by FTC Chairwoman Edith Ramirez on Appellate Ruling in the St. Luke’s Hospital Matter
FTC Approves Final Orders In PaymentsMD Privacy Case
FTC Puts Conditions on Sun Pharmaceutical’s Proposed Acquisition of Ranbaxy
Statement of Chairwoman Edith Ramirez, Commissioner Julie Brill, and Commissioner Terrell McSweeny - Federal Trade Commission v. Genesis Today, Inc., Pure Health LLC, and Lindsey Duncan
FTC Approves Final Order Preserving Future Competition in the Market for Drug-coated Balloon Catheters Used to Treat Peripheral Artery Disease
Medtronic, Inc. and Covidien plc, In the Matter of
Global medical technology company Medtronic, Inc. agreed to divest the drug-coated balloon catheter business of Ireland-based medical products company Covidien plc, in order to settle FTC charges that its $42.9 billion acquisition of Covidien would likely be anticompetitive. Under the FTC’s proposed settlement, Medtronic will sell the drug-coated balloon catheter business to a Colorado-based medical device company, The Spectranetics Corporation. According to the FTC’s complaint, both Medtronic and Covidien are developing drug-coated balloon catheters to compete with C.R. Bard, Inc., which currently is the only company that supplies these products, used to treat peripheral artery disease, in the U.S. market. Medtronic and Covidien are the only companies with products in clinical trials in the Food and Drug Administration’s approval process, which makes it unlikely that other competitors could enter the market in time to counteract the effects of the merger.
Opinion: Antitrust Enforcement in Health Care – Controlling Costs, Improving Quality
FTC Requests Public Comments on Application from Owners of Surgery Center Holdings, Inc. for Approval to Divest Assets in Central Florida
FTC Staff Urges Dental Accreditation Commission To Adopt Dental Therapy Accreditation Standards
FTC Puts Conditions on Medtronic’s Proposed Acquisition of Covidien
FTC Requires Divestiture as a Condition of Surgery Center Holdings' Acquisition of Competitor Symbion
Displaying 721 - 740 of 1585